Dan Brickey was stunned when he learned the news. The cost of the cystic fibrosis medicine that his 2-year-old daughter, Ali, had recently started taking was about to climb from just $180 out of pocket each year to a whopping $43,600 in 2023.

After a college student finally found a treatment that worked, the insurance giant decided it wouldn’t pay for the costly drugs. His fight to get coverage exposed the insurer’s hidden procedures for rejecting claims.

The rising price of prescription drugs has sparked outrage for more than a decade. That’s largely because medications aren’t like other expensive products.

As a health and science reporter, I’ve studied the maze of U.S. health care. But when my son got sick, I still got lost.

AbbVie for years delayed competition for its blockbuster drug Humira, at the expense of patients and taxpayers. The monopoly is about to end.

As the cost of medication soars, patients are turning to online coupons and financial assistance programs.

In 2021, Humira, the blockbuster biologic that has for years been the highest grossing drug in the world, accomplished something that no drug had previously achieved when its global revenues topped $20 billion.

U.S. drugmaker Merck & Co (MRK.N) hopes to patent a new formulation of its $20 billion cancer immunotherapy Keytruda that can be injected under the skin, allowing it to protect its best-selling drug from competition expected as soon as 2028.

More than 1.3 million American adults with diabetes skipped doses, delayed buying or otherwise rationed doses of insulin due to escalating cost of the life-saving medication, a new study found.

For decades Americans have spent more on prescription drugs than people in other countries. The Biden Administration has been involved in ongoing efforts to stem this trend, making prescription drugs more affordable to both improve public health and provide economic relief to Americans.